High‐Resolution HLA Class I Genotyping Using G‐Seq Platform‐Based Nanopore Long‐Read Sequencing Integrated With the HLATyper Pipeline
HLA · 2026
DOI: 10.1111/tan.71051 ↗Kurz gefasst
Fachartikel in der Zeitschrift HLA, 2026. Verfasst von Hong-Hong He und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Transfusion Research Laboratory, Suzhou Blood Center, Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Nanopore Sequencing, Histocompatibility Testing, Genotyping Techniques, High-Throughput Nucleotide Sequencing. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Gusu Talent Program, Suzhou Science and Technology Plan Project, Jiangsu Provincial Health Commission Project.
Abstract (Originalsprache)
This study evaluated the performance and clinical applicability of a novel third‐generation sequencing (TGS) strategy for high‐resolution HLA class I genotyping, employing nanopore long‐read sequencing combined with a dedicated analytical workflow, HLATyper. A total of 49 clinical samples were analysed in parallel using conventional PCR‐based sequence‐based typing (PCR‐SBT) and a TGS‐based approach on the G‐seq500 platform with the in‐house‐developed HLATyper pipeline. Genotyping results for HLA‐A, ‐B and ‐C loci were compared between the two methods with respect to concordance, typing resolution and the ability to resolve ambiguous allele assignments. Ambiguity rates between the two methods were evaluated using Fisher's exact test. Complete concordance was observed between PCR‐SBT and the TGS method at the two‐field level across all samples. Ambiguous allele assignments were detected in 63.27% (31/49) of cases using PCR‐SBT, whereas the TGS strategy produced a single, unambiguous genotype for every sample ( p < 0.0001). Furthermore, TGS enabled assignment of four‐field typing through comprehensive sequence alignment and successfully resolved ambiguities and exonic coverage gaps inherent to short‐read approaches. G‐seq500 platform‐based nanopore long‐read sequencing combined with the HLATyper analytical pipeline enables high‐resolution, unambiguous and comprehensive HLA class I genotyping. This integrated strategy represents a valuable complementary approach for clinical applications requiring precise HLA matching, such as transplantation and platelet transfusion support.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Transfusion Research Laboratory, Suzhou Blood Center, Suzhou, Jiangsu, China.
- Key Laboratory of Bio-Resources and Eco-Environment of Ministry of Education, Southwest Bio-resources R&D Key Laboratory of Sichuan Province, Laboratory for Ex Situ Conservation and Resource Utilization of Mountain Plan…
- Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Peking Union Medical College, Chengdu, Sichuan, China.
ORCID-Profile: Hong-Hong He, Run-Yu Xu, Qiu-Lei Zhong, Ming-Yuan Wang, Miao He, Long-Hai Tang
Förderung
- Gusu Talent Program
- Suzhou Science and Technology Plan Project
- Jiangsu Provincial Health Commission Project
- Suzhou Municipal Clinical Medical Expert Team Introduction Program 2026
- Key R&D Support Plan of the Science and Technology Bureau of Chengdu
Zitieren
APA
He, H. H., Xu, R. Y., Zhong, Q. L., Yu, Y., Wang, M. Y., He, M., & Tang, L. H. (2026). High‐Resolution HLA Class I Genotyping Using G‐Seq Platform‐Based Nanopore Long‐Read Sequencing Integrated With the HLATyper Pipeline. HLA. https://doi.org/10.1111/tan.71051
Vancouver
He HH, Xu RY, Zhong QL, Yu Y, Wang MY, He M, et al. High‐Resolution HLA Class I Genotyping Using G‐Seq Platform‐Based Nanopore Long‐Read Sequencing Integrated With the HLATyper Pipeline. HLA. 2026. doi:10.1111/tan.71051
BibTeX
@article{He2026,
author = {He, Hong-Hong and Xu, Run-Yu and Zhong, Qiu-Lei and Yu, Yan and Wang, Ming-Yuan and He, Miao and Tang, Long-Hai},
title = {High‐Resolution HLA Class I Genotyping Using G‐Seq Platform‐Based Nanopore Long‐Read Sequencing Integrated With the HLATyper Pipeline},
journal = {HLA},
year = {2026},
doi = {10.1111/tan.71051}
}
EUVIMED